[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peri-procedural-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peri-procedural-myocardial-infarction":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100658287","clinical-evidence-with-biomarker-confirmation-for-ppmi-in-pci-clinical-trials-study-100658287",false,"NCT07848529","Clinical Evidence With Biomarker Confirmation for PPMI in PCI Clinical Trials Study","CEC-PPMI","Inclusion Criteria:\n\n1. Subject age is ≥ 18 years or minimum legal age as required by local regulations.\n2. Documented stable angina or functional testing demonstrating ischemia; or stabilized non-ST elevation acute coronary syndrome defined as negative or confirmed declining site determined biomarker.\n3. Subject is eligible for dual anti-platelet therapy treatment with aspirin plus either, clopidogrel, prasugrel, or ticagrelor.\n4. Life expectancy \\>1 year in opinion of investigator.\n5. Subject is willing and able to provide informed consent and comply with study procedures and required follow-up evaluations.\n\nExclusion Criteria:\n\n1. ST elevation myocardial infarction within 7 days\n2. Non-ST elevation myocardial infarction without stable or declining biomarkers.\n3. Previous percutaneous coronary intervention within 7 days.\n4. Inability to comply with recommended duration of dual anti-platelet therapy.\n5. Decompensated heart failure.","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","The goal of this prospective, multicenter, non-randomized observational study is to better identify and understand periprocedural myocardial injury among adults undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease or stabilized non-ST-elevation acute coronary syndrome. The main questions it aims to answer are:\n\n* Can a clinical criteria checklist identify patients with an increased likelihood of cardiac biomarker elevation following PCI?\n* Are positive clinical criteria and different post-PCI levels of troponin I, troponin T, and CK-MB associated with all-cause mortality or hospitalization for heart failure at one year? Researchers will compare participants with a positive clinical criteria checklist with those with a negative checklist to assess differences in post-PCI biomarker elevations and one-year clinical outcomes. Outcomes will also be compared between participants discharged on the same day and those hospitalized overnight.\n\nParticipants will:\n\n* Undergo PCI using commercially approved devices according to local standards of care.\n* Have blood samples collected before and after PCI to measure cardiac biomarkers.\n* Have relevant clinical and PCI procedural information collected, including completion of a clinical criteria checklist by the study team before discharge.\n* Be followed for one year to determine whether they have died from any cause or been hospitalized for heart failure.",[24,25,26,27,28],"Peri-procedural Myocardial Infarction","Heart Failure Hospitalization","Mortality","Stable Angina Pectoris","Non ST Elevation Myocardial Infarction (NSTEMI)",[30,31,32],"PCI","Coronary artery disease","biomarkers","NOT_YET_RECRUITING","2026-09-23",{"date":36,"type":37},"2026-09-30","ACTUAL",{"date":39,"type":20},"2026-12",{"date":41,"type":20},"2029-12",{"name":43,"class":44},"Baim Institute for Clinical Research","OTHER"]